News

Letter from the Chairs

From our 2011 Annual Report.

 

Dear Friends,

On behalf of the Board of Directors and the Research Consortium, we want to thank all the donors, researchers and academic institutional partners supporting Cure Alzheimer’s Fund research for your help in making 2011 such a successful science year. Guided by leading scientists in the field, Cure Alzheimer’s Fund-supported research continues to make breakthrough progress toward our goal of eradicating Alzheimer’s disease.

TREM2: New candidate gene for AD

Rudy Tanzi, Chair, Cure Alzheimer's Fund Research Consortium comments here on the AP article appearing on this topic today:

The Roadmap to Therapies 2012

Alzheimer’s is the sixth leading cause of death in the United States, but its most devastating effects can’t be counted. The disease steals away memories; it turns loved ones into strangers; it makes home unfamiliar and takes away all the things that define an individual. And, until recently, there’s been little hope of stopping its progress.

Cure Alzheimer’s Fund was founded to support cutting-edge, high-potential research to help the Alzheimer’s research community get on a smarter, faster trajectory toward a cure.

Origins of Alzheimer's Increasingly Clear

Consensus among Alzheimer’s researchers about the origins of the disease is growing. Most, including members of Cure Alzheimer’s Fund Research Consortium, agree that a combination of factors, beginning with the excessive build-up of the peptide Abeta42  triggering  the development of tau tangles, nerve cell death, and inflammation are all required for Alzheimer’s pathology.

David M. Holtzman, M.D., Receives Brain Research Foundation Award For Community Service

(October 29, 2012) (PRWEB) October 30, 2012 -- The Brain Research Foundation (BRF) today announced that the 2012 recipients of the Frederic A. Gibbs Discovery Award will be Michael W. Ferro Jr. and David M. Holtzman, M.D.

$5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development

Largest Single Private Investment in Alzheimer’s Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development

Understanding who is most susceptible to Alzheimer’s disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private scientific grant ever invested in Alzheimer’s Whole Genome Sequencing (WGS) focused on families afflicted with the disease.

In Memory of Arlen Specter

Cure Alzheimer's Fund is saddened to learn of the death of Senator Arlen Specter. He was a strong supporter of funding for medical and scientific research.

His commitment to medical research and his memory will live on through the Accelerated Cures Network, which he worked tirelessly on and which will help to speed the development of therapies and hopefully cures for many diseases.

Eli Lilly Drug Slows Decline in Early-Stage Patients

October 9 -- Eli Lilly announced encouraging results yesterday involving their experimental drug Solanezumab. Solanezumab is an antibody aimed at lowering beta-amyloid levels in the brain. In trials lasting 18 months, patients with mild Alzheimer's symptoms taking Solanezumab showed significantly less cognitive decline -- 34% less -- compared with patients taking the placebo.

We Look to our Researchers for Hope!

Cure Alzheimer’s Fund Research Consortium member and funded researcher Steven L. Wagner, Ph.D., Principle Investigator, Department of Neurosciences; School of Medicine, and William C. Mobley, M.D., Ph.D., Distinguished Professor and Chair of the Department of Neurosciences, both from the University of California, San Diego, discuss how research into the cause of Alzheimer’s disease brings hope to patients and caregivers, and the role that Cure Alzheimer’s plays in the process.